首页> Clinical lymphoma, myeloma & leukemia> Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice

导出原文传递

翻译打印收藏纠错

第一作者： Sanford, David S.

作者： Sanford, David S. ^[1] ; Wierda, William G. ; Burger, Jan A. ; Keating, Michael J. ; O'Brien, Susan M.

作者单位： Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA ^[1]

关键词 Anti-CD20 antibody BTK inhibitor Lymphoid malignancy Novel agents PI3K inhibitor

发布时间 2015-12-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical lymphoma, myeloma & leukemia

2015年15卷7期

385-391页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Clinical lymphoma, myeloma & leukemia

2015年15卷7期

385-391页

检索历史清除

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice

Clinical lymphoma, myeloma & leukemia

相似文献

同项目论文

Clinical lymphoma, myeloma & leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice

Clinical lymphoma, myeloma & leukemia

相似文献

同项目论文

Clinical lymphoma, myeloma & leukemia

相关期刊

检索历史清除